Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price rose 1.3% on Tuesday. The stock traded as high as $1,177.06 and last traded at $1,157.6060. Approximately 2,121,006 shares traded hands during trading, a decline of 29% from the average session volume of 2,977,780 shares. The stock had previously closed at $1,143.12.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Oncology expansion: The FDA granted orphan-drug designation to experimental cancer treatment olomorasib for pancreatic cancer, potentially providing development incentives and future market exclusivity. The FDA also expanded Jaypirca’s approval into the first-line CLL/SLL setting, broadening Lilly’s commercial cancer portfolio. Lilly oncology FDA developments
• Positive Sentiment: Obesity pipeline momentum: Data presented for Lilly’s oral GLP-1 candidate Foundayo showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. Investors see a potential oral treatment as an important growth catalyst, while early work targeting the amylin pathway could support next-generation obesity-drug combinations. Foundayo clinical data
• Positive Sentiment: Pipeline and partnerships: Lilly completed early trials for a new basal-insulin candidate and advanced Phase 1 development of eltrekibart. It also expanded its Gate Bioscience drug-discovery collaboration, potentially worth more than $870 million, and joined a $120 million financing for healthcare company General Medicine. Gate Bioscience collaboration
• Positive Sentiment: Broader growth prospects: Analysts and financial commentators highlighted triple-digit growth in parts of Lilly’s oncology, immunology and neuroscience businesses, alongside continued leadership in metabolic health. Lilly’s TuneLab collaboration with insitro is also making machine-learning models available to selected biotech companies, potentially strengthening its innovation ecosystem. Lilly growth opportunity beyond weight loss
• Neutral Sentiment: Upcoming data: Lilly plans 21 dermatology presentations covering Ebglyss, Taltz and Zepbound-related research at the Fall Clinical Dermatology Conference. The updates could provide additional pipeline visibility but are not yet commercial results. Lilly dermatology data
• Negative Sentiment: Valuation concerns: LLY trades at a substantial premium to the broader market, meaning continued rapid growth is already reflected in the share price. Commentary also flagged potential pressure from falling U.S. prices for Mounjaro and Zepbound, leaving limited room for clinical, regulatory or commercial disappointments. Lilly valuation risk

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LLY shares. Sanford C. Bernstein boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. HSBC increased their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,311.96.

Eli Lilly and Company Trading Up 1.3%

The stock has a market cap of $1.09 trillion, a PE ratio of 38.85, a PEG ratio of 1.40 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a fifty day simple moving average of $1,175.28 and a two-hundred day simple moving average of $1,090.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the firm earned $6.31 EPS. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of LLY. Osbon Capital Management LLC bought a new position in Eli Lilly and Company in the 4th quarter worth $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $30,000. Maseco LLP lifted its holdings in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. boosted its position in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after acquiring an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.